Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
BETTERLIFE PHARMA INC. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners across 2 distinct art units. This total dispersion suggests that the company's current patent activity, though small in volume, covers different technical niches within the pharmaceutical field. The 2 pending office actions are being reviewed independently by different groups at the USPTO.
O DELL, DAVID K is the busiest examiner for the portfolio, managing 1 pending office action. With 2 distinct examiners and 2 distinct art units involved, there is no overlap in the prosecution of the 2 pending office actions. This requires the company to manage two separate sets of examination standards and examiner preferences. Practitioners should be prepared to address the specific requirements of each of the 2 distinct art units to successfully navigate the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283373 | METHODS OF TREATING MENTAL AND/OR MOOD DISORDERS USING 2-BROMO-LSD ALONE OR IN COMBINATION WITH A MTOR INHIBITOR | O DELL, DAVID K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283373 | METHODS OF TREATING MENTAL AND/OR MOOD DISORDERS USING 2-BROMO-LSD ALONE OR IN COMBINATION WITH A MTOR INHIBITOR | O DELL, DAVID K | — |
| 17949183 | LSD DERIVATIVES, SYNTHESIS & METHOD FOR TREATMENT OF DISEASES AND DISORDERS | MOORE, SUSANNA | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18283373 | METHODS OF TREATING MENTAL AND/OR MOOD DISORDERS USING 2-BROMO-LSD ALONE OR IN COMBINATION WITH A MTOR INHIBITOR | O DELL, DAVID K | 1621 | §102§103§112Other | Non-Final OA | — | Pending | Sep 21, 2023 |
| 17949183 | LSD DERIVATIVES, SYNTHESIS & METHOD FOR TREATMENT OF DISEASES AND DISORDERS | MOORE, SUSANNA | 1624 | §112DP | Non-Final OA | — | Pending | Sep 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBETTERLIFE PHARMA INC. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
David K O Dell has the most, with 1 of BETTERLIFE PHARMA INC.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
